
Cardinal Health, Inc.
NYSE•CAH
CEO: Mr. Jason M. Hollar
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1983-08-04
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products, as well as medical supplies. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; offers pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression solution, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Additionally, it manufactures, prepares, delivers, and distributes radiopharmaceuticals and related treatments; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Contact Information
Market Cap
$47.24B
P/E (TTM)
29.7
31.5
Dividend Yield
1.0%
52W High
$214.93
52W Low
$114.60
52W Range
Rank20Top 4.7%
6.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q1 2026 Data
Revenue
$64.01B+22.44%
4-Quarter Trend
EPS
$1.89+10.53%
4-Quarter Trend
FCF
$865.00M-149.80%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Revenue and Earnings Surge Total revenue reached $64.0 B, increasing 22 percent; Non-GAAP operating earnings grew 37 percent to $857 M this quarter.
Strong Non-GAAP EPS Growth Non-GAAP diluted EPS increased 36 percent to $2.55 per share for the quarter, driven by acquisitions and product growth.
Pharma Segment Profit Rises Pharmaceutical segment profit increased 26 percent to $667 M, benefiting from MSO acquisitions and branded/specialty sales contribution.
Cash Position Strengthened Cash and equivalents grew to $4.6 B by September 30, 2025; operating cash flow provided $973 M this period.
Risk Factors
Healthcare Environment Changes Regulatory shifts, including value-based payments and potential drug pricing orders, may adversely affect demand and profitability.
Supply Constraints Impact GLP-1 Increased GLP-1 pharmaceutical sales did not meaningfully contribute to segment profit due to unpredictable demand and supply constraints.
Tariff Cost Uncertainty Imposed or threatened U.S. tariffs resulted in substantial additional sourcing costs, potentially impacting financial results if not offset.
Acquisition Integration Risks Successful integration of MSO platforms depends on retaining local providers, managing reimbursement, and competition from others.
Outlook
Solaris Health Acquisition Definitive agreement signed to acquire urology MSO Solaris Health for approximately $1.9 B in cash, subject to adjustments.
Capital Deployment Focus Deployed $500 M for debt repayment and $375 M for share repurchases during the quarter using available cash.
GMPD Segment Growth Expected Expect further growth in Global Medical Products segment sales during the remainder of fiscal 2026 and beyond based on current trends.
Debt Financing Secured Issued new long-term debt, receiving net proceeds of approximately $1.0 B to fund part of the Solaris Health consideration.
Peer Comparison
Revenue (TTM)
CAH$234.31B
HUM$126.36B
$21.66B
Gross Margin (Latest Quarter)
86.1%
77.9%
64.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| EW | $50.61B | 36.9 | 13.4% | 5.3% |
| CAH | $47.24B | 29.7 | -55.0% | 16.4% |
| INSM | $43.51B | -36.5 | -183.6% | 31.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.0%
Steady Growth
4Q Net Income CAGR
4.0%
Profitability Slowly Improving
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Jan 29, 2026
EPS:$2.31
|Revenue:$64.88B
Reports
All Years
Form 10-Q - Q1 2026
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $64.01B+22.4%|EPS: $1.89+10.5%MissForm 10-K - FY 2025
Period End: Jun 30, 2025|Filed: Aug 12, 2025|Revenue: $222.58B-1.9%|EPS: $6.48+86.2%BeatForm 10-Q - Q3 2025
Period End: Mar 31, 2025|Filed: May 1, 2025|Revenue: $54.88B+0.0%|EPS: $2.11+97.2%MeetForm 10-Q - Q2 2025
Period End: Dec 31, 2024|Filed: Jan 30, 2025|Revenue: $55.26B-3.8%|EPS: $1.65+10.0%MissForm 10-Q - Q1 2025
Period End: Sep 30, 2024|Filed: Nov 1, 2024|Revenue: $52.28B-4.3%|EPS: $1.71+8450.0%BeatForm 10-K - FY 2024
Period End: Jun 30, 2024|Filed: Aug 14, 2024|Revenue: $226.83B+10.7%|EPS: $3.48+176.2%BeatForm 10-Q - Q3 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $54.87B+8.7%|EPS: $1.07-20.7%MissForm 10-Q - Q2 2024
Period End: Dec 31, 2023|Filed: Feb 1, 2024|Revenue: $57.44B+11.6%|EPS: $1.50-400.0%Miss